^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD3D (CD3d Molecule)

    i
    Other names: CD3D, CD3d Molecule, CD3d Antigen, Delta Polypeptide (TiT3 Complex), T-Cell Surface Glycoprotein CD3 Delta Chain, CD3d Molecule, Delta (CD3-TCR Complex), T-Cell Receptor T3 Delta Chain, T3D, CD3 Antigen, Delta Subunit, OKT3, Delta Chain, CD3d Antigen, CD3-DELTA, CD3 Delta, IMD19
    5ms
    Calcitonin Alleviates Sepsis-Induced Acute Lung Injury by Inhibiting the HMGB1/MyD88/NF-κB Pathway by Targeting CD3D. (PubMed, Front Biosci (Landmark Ed))
    CD3D exacerbates sepsis-induced ALI by potentiating the HMGB1/MyD88/NF-κB pathway and NLRP3 inflammasome, driving inflammation and oxidative stress. Combined CD3D knockdown and calcitonin treatment offers a novel synergistic therapeutic strategy for mitigating pulmonary endothelial injury in sepsis.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • CD3D (CD3d Molecule) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    6ms
    Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer. (PubMed, Cancer Immunol Immunother)
    This study establishes MLKL as a master regulator of anti-tumor immunity in OC, driving chemokine-mediated immune cell recruitment and TME reprogramming. The novel NecropImmScore is a multifaceted biomarker that effectively predicts prognosis, immunotherapy response, BRCA1 deficiency, and chemosensitivity, offering significant potential for guiding precision therapeutic strategies in OC.
    Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • LAG3 (Lymphocyte Activating 3) • CCR4 (C-C Motif Chemokine Receptor 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • GZMB (Granzyme B) • CD3D (CD3d Molecule) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase)
    |
    PD-L1 expression • HRD
    |
    cisplatin • gemcitabine • paclitaxel
    8ms
    Tumor Immune Response as a Biomarker for Metastasis-Free Survival of Breast Cancer and Immune Checkpoint Inhibition Therapy: A Retrospective Cohort Study. (PubMed, Breast Cancer (Auckl))
    Tumor IR is a biomarker for MFS for BRCs of I, II, and IV subtypes. Our study supports the potential use of the IR score for identifying patients responsive to ICIT.
    Retrospective data • Journal • Checkpoint inhibition • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma) • CD3D (CD3d Molecule)
    |
    HER-2 overexpression
    9ms
    Preoperative MRI-based radiomics analysis of intra- and peritumoral regions for predicting CD3 expression in early cervical cancer. (PubMed, Sci Rep)
    The SVM algorithm achieved the highest predictive performance for CD3 T-cell expression status, with an area under the curve (AUC) of 0.93 in the training group and 0.92 in the test group. This MR-based radiomics model effectively predicts CD3 expression status in patients with early-stage CC, offering a non-invasive tool for preoperative assessment of CD3 expression, but its clinical utility needs further prospective validation.
    Retrospective data • Journal
    |
    CD3D (CD3d Molecule) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    10ms
    TGFB2 Gene Methylation in Tumors with Low CD8+ T-Cell Infiltration Drives Positive Prognostic Overall Survival Responses in Pancreatic Ductal Adenocarcinoma. (PubMed, Int J Mol Sci)
    Current treatment options are limited to cytotoxic standard therapies, primarily FOLFIRINOX or modified FOLFIRINOX regimens...TGFB2 methylation is a prognostic marker for PDAC patients within an immunosuppressed tumor microenvironment characterized by low CD8+ T-cell infiltration. This correlation is functionally associated with TGFB2 mRNA production, suggesting that targeting TGFB2 mRNA through knockdown can potentially enhance PDAC prognosis.
    Journal
    |
    CD8 (cluster of differentiation 8) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • CD3D (CD3d Molecule) • IFI27 (Interferon Alpha Inducible Protein 27) • RAC2 (Rac Family Small GTPase 2) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    12ms
    Pathogenomic fingerprinting to identify associations between tumor morphology and epigenetic states. (PubMed, Eur J Cancer)
    This computational approach is the first to assess the correlation between pathomic and epigenetic features in the context of cancer.
    Journal
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule) • CD79A (CD79a Molecule) • CD3D (CD3d Molecule)
    1year
    Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. (PubMed, J Thorac Oncol)
    In our cohort of 10 patients with relapsed SCLC and untreated brain metastases, including those with symptomatic intracranial disease and one with suspected leptomeningeal disease, clinical response or stability was seen in 90% of patients. We present several cases in which rapid, dramatic radiographic responses and clinical improvement were observed in patients with innumerable growing brain metastases (>20 lesions) who would otherwise require whole brain radiation, suggesting that tarlatamab can control intracranial metastases as monotherapy, potentially sparing or deferring the need for brain radiation.
    Journal • Real-world evidence
    |
    CD3D (CD3d Molecule)
    |
    Imdelltra (tarlatamab-dlle)
    1year
    Landscape of four different stages of human gastric cancer revealed by single-cell sequencing. (PubMed, World J Gastrointest Oncol)
    This study provides a comprehensive analysis of cell dynamics across GC stages, highlighting key interactions within the tumor microenvironment. These findings offer valuable insights for developing novel therapeutic strategies.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • EPCAM (Epithelial cell adhesion molecule) • CD3D (CD3d Molecule) • KRT19 (Keratin 19) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    over1year
    Immune Subtypes and Characteristics of Endometrial Cancer Based on Immunogenes. (PubMed, Cancer Manag Res)
    EC can be divided into two immune subtypes based on immunogenes. Low expression of S100A9 and high expression of IL2RB, HLA-DRB1, CD3E, and CD3D suggest sensitivity to immunotherapy and a good prognosis.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • S100A9 (S100 Calcium Binding Protein A9) • CD3D (CD3d Molecule) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    S100A9 expression
    over1year
    Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21). (SABCS 2024)
    TIL-high tumors were associated with immune-enriched cancer including BLIA and TME subtypes. Ongoing analysis of invasive disease-free survival as the primary endpoint in each arm of MIRINAE trial and the role of atezolizumab in association with genomic features will provide deeper insights into the role of ICIs as adjuvant therapy.
    P2 data • Clinical • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • PALB2 (Partner and localizer of BRCA2) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IRF4 (Interferon regulatory factor 4) • CD3D (CD3d Molecule) • GZMK (Granzyme K) • NDRG1 (N-Myc Downstream Regulated 1)
    |
    TP53 mutation • BRCA1 mutation • PIK3CA mutation • PALB2 mutation • PIK3R1 mutation
    |
    FoundationOne® CDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Tecentriq (atezolizumab) • capecitabine
    over1year
    Construction of a five-gene-based prognostic model for relapsed/refractory acute lymphoblastic leukemia. (PubMed, Hematology)
    We have developed a risk prediction model for pediatric R/R ALL utilizing the genes BAG2, EPHA4, FBXO9, SNX10, and WNK1. This model provides a scientific foundation for early identification of R/R ALL in children.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SOX2 • CD27 (CD27 Molecule) • CD3D (CD3d Molecule) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • WNK1 (WNK Lysine Deficient Protein Kinase 1) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • NANOG (Nanog Homeobox) • RASGRP1 (RAS Guanyl Releasing Protein 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • BLNK (B Cell Linker) • E2F1 (E2F transcription factor 1) • EPHA4 (EPH Receptor A4) • FBXO9 (F-Box Protein 9) • HOXB4 (Homeobox B4)
    over1year
    Dual Role of Necroptosis in Cervical Cancer: Promoting Tumor Aggression and Modulating the Immune Microenvironment via the JAK2-STAT3 Pathway. (PubMed, J Cancer)
    Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), was also evaluated for its potential induction of necroptosis in CC cells and its interaction with necroptosis inhibitors...This study reveals a complex interaction between necroptosis, tumor progression, and the immune response in CC. The findings propose a nuanced approach to leveraging necroptosis for therapeutic interventions, highlighting the potential of combining necroptosis inhibitors with existing therapies to improve treatment outcomes in CC.
    Journal
    |
    CD3D (CD3d Molecule)
    |
    VEGFA expression
    |
    Avastin (bevacizumab)